Conclusion : This meta‐ analysis has shown that fibrate treatment  significantly decreases fasting plasma glucose , insulin levels , and HOMA‐IR indicating additional clinical therapeutic benefits .
Aims : The aim of this meta‐ analysis of r and omized placebo‐controlled clinical trials was to assess the effect of fibrates on glycemic parameters .
Ciprofibrate therapy improves endothelial function and reduces postprandial lipemia and oxidative stress in type 2 diabetes mellitus.
BACKGROUND Exaggerated postpr and ial lipemia ( PPL ) is a factor in atherogenesis , involving endothelial dysfunction and enhanced oxidative stress . We examined the effect of ciprofibrate therapy on these parameters in type 2 diabetes mellitus . METHODS AND RESULTS Twenty patients entered a 3-month , double-blind , placebo-controlled  study . Each subject was studied fasting and after a fatty meal , at baseline , and after 3 months of treatment .  Glucose and lipid profiles were measured over an 8-hour postpr and ial period . Endothelial function ( flow-mediated endothelium-dependent vasodilatation [ FMD ] ) and oxidative stress ( electron paramagnetic resonance spectroscopy ) were measured after fasting and 4 hours postpr and ially . At baseline , both groups exhibited similar PPL and deterioration in endothelial function . After ciprofibrate , fasting and postpr and ial FMD values were significantly higher ( from 3.8+/-1 . 8 % and 1.8+/-1.3 % to 4.8+/-1.1 % and 3.4+/-1.1 % ; P<0.05 ) . This was mirrored by a fall in fasting and postpr and ial triglycerides ( 3 . 1+/-2.1 and 6.6+/-4.1 mmol/L to 1.5+/-0.8 and 2.8+/-1.3 mmol/L , P<0 . 05 ) . Fasting and postpr and ial HDL cholesterol was also elevated ( 0 . 9+/-0.1 and 0.8+/-0.1 mmol/L and 1.2+/-0.2 and 1.2+/-0.1 mmol/L , P<0 . 05 ) . There were no changes in total or LDL cholesterol . Fasting and postpr and ial triglyceride enrichment of all lipoproteins was attenuated , with cholesterol depletion of VLDL and enrichment of HDL . There were similar postpr and ial increases in oxidative stress in both groups at baseline , which was significantly attenuated by ciprofibrate ( 0.3+/-0.6 versus 1.5+/-1.1 U , P<0.05 ) . CONCLUSIONS This study demonstrates that fibrate therapy improves fasting and postpr and ial endothelial function in type 2 diabetes . Attenuation of PPL and the associated oxidative stress , with increased HDL cholesterol levels , may be important
Conclusion : This meta‐ analysis has shown that fibrate treatment  significantly decreases fasting plasma glucose , insulin levels , and HOMA‐IR indicating additional clinical therapeutic benefits .
Aims : The aim of this meta‐ analysis of r and omized placebo‐controlled clinical trials was to assess the effect of fibrates on glycemic parameters .